DE954910C - Manufacture of metabolic products that inhibit bacterial growth - Google Patents

Manufacture of metabolic products that inhibit bacterial growth

Info

Publication number
DE954910C
DE954910C DEL16639A DEL0016639A DE954910C DE 954910 C DE954910 C DE 954910C DE L16639 A DEL16639 A DE L16639A DE L0016639 A DEL0016639 A DE L0016639A DE 954910 C DE954910 C DE 954910C
Authority
DE
Germany
Prior art keywords
bacterial growth
metabolic products
manufacture
inhibit bacterial
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DEL16639A
Other languages
German (de)
Inventor
Dr Wolfgang Laves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DEL16639A priority Critical patent/DE954910C/en
Application granted granted Critical
Publication of DE954910C publication Critical patent/DE954910C/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Description

Herstellung von Stoffwedhselprodukten mit das Bakterienwachstum hemmender Wirkung Es ist bekannt, daß die im menschlichen Darm vorkommenden Bakterien, z. B. Coli-Bakterien sowie Enterokokken, gewisse physiologische Aufgaben haben, die nicht nur in der Zerkleinerung und Aufteilung der Nahrung, sondern auch in der Produktion lebenswidhtiger Fermente und Vitamine wie p-Aminobenzoesäure, Pantothensäure, Vitamin K, Vitamine B1, B2, B6, B12 bestehen.Manufacture of fabric swirl products with inhibiting bacterial growth effect It is known that the bacteria occurring in the human intestine, e.g. B. Coli bacteria, as well as enterococci, have certain physiological functions that they do not only in the chopping and splitting of the food, but also in the production non-life ferments and vitamins such as p-aminobenzoic acid, pantothenic acid, vitamins K, vitamins B1, B2, B6, B12 consist.

Es wurde nun gefunden, daß solche Bakterien außerdem Substanzen antibiotischer, bakteriostatischer und biogenetischer Wirkung erzeugen bzw. das Wachstum körperfremder Bakterien - Bact. proteus, Hefen - verzögern oder verhindern, wenn bekannten Nährlösungen, z. B. It has now been found that such bacteria also contain substances of antibiotic, produce bacteriostatic and biogenetic effects or the growth of exogenous substances Bacteria - Bact. proteus, yeasts - delay or prevent, if known nutrient solutions, z. B.

Glukoselösung, bei submerser Bebrütung menschliches Eiweiß in natura (Ascites oder Blutserum) und anschließend Coli-Bakterien zugesetzt werden, wobei das Wachstum der Coli-Bakterien über Tage verfolgt wird, bis ein Endwachstum durch Beendigung sowohl am pu-Wert als auch durch die mangelnde Gasentwicklung dieser Lösung festgestellt und darauf diese Lösung durch kurze Erhitzung vom Eiweiß getrennt wird, da dieses infolge der Erhitzung koaguliert. Durch nachfolgende Neutralisation und Filtration wird eine klare bakterienfreie und eiweißfreie Lösung gewonnen, die so verarbeitet oder in diesem Zustand verwendet werden kann.Glucose solution, with submerged incubation human protein in kind (Ascites or blood serum) and then coli bacteria are added, whereby the growth of the coliform bacteria is followed for days until a final growth occurs Termination both at the pu value and due to the lack of gas development in this Solution determined and then this solution separated from the egg white by brief heating as this coagulates as a result of the heating. Through subsequent Neutralization and filtration, a clear, bacteria-free and protein-free solution is obtained which processed or used in this state.

Die so erhaltene Lösung enthält, wie wissenschaftliche Teste ergeben haben, Coli-Stoffwechselprodukte. So hat sich am Plattentest der Nachweis ergeben, daß Hefen, Mikrococcus aureus oder Bact. enteritis Gärtner teils vollständig, teils über längere Zeit, gehemmt werden. In diesen Versuchen sieht man bei Hefe eine antibiotische, bei Mikrococcus @@@@@ und Bact. enteritis Gärtner eine bakteriostatische Wirkung, während gegenüber dem normalen Bact. coli eine biogenetische Wirkung festgestellt worden ist. Vergleiche im Lochtest mit Penicillin 50 Einheiten und den verschiedenen Stoffwechselkonzentraten von Coli-Stoffwechselprodukten ergaben, daß deutliche Hemmringe, also eine bakteriostatische Wirkung gegenüber dem toxischen Coli o III, stattfanden. The resulting solution contains, as shown by scientific tests have coli metabolic products. The plate test showed that that yeast, Mikrococcus aureus or Bact. enteritis gardener partly complete, partly be inhibited over a long period of time. In these experiments one sees an antibiotic, at Mikrococcus @@@@@ and Bact. enteritis gardener a bacteriostatic effect, while opposite the normal Bact. coli found a biogenetic effect has been. Compare in the hole test with penicillin 50 units and the various Metabolic concentrates of Coli metabolic products showed that clear inhibition rings, thus a bacteriostatic effect against the toxic Coli o III took place.

Beispiel In einem Literkolben wird etwa 700 ccm iO/oige Glukoselösung steril mit sterifiltrierter menschlicher Ascites versett, so daß etwa ein Eiweißgehalt von 1/2 0/o für die Gesamtlösung zugrunde gelegt wird. Sollte die Ascites 4% Eiweiß enthalten, werden 100 ccm benötigt, sollte sie 2,25% enthalten, werden 200 ccm benötigt. Dieser Ascitesflüssigkeit wird eine Absohwemmung physiologisch hochwertiger Coli-Bakterien zugesetzt. Die Bebrütung wird durch Entnahme täglich kontrolliert. Example In a liter flask is about 700 ccm iO / o glucose solution sterile with sterile filtered human ascites, so that about a protein content of 1/2 0 / o is used as the basis for the overall solution. The ascites should be 4% protein contain, 100 ccm are required, if it contains 2.25%, 200 ccm are required. This ascites fluid becomes a desquamation of physiologically valuable coli bacteria added. The incubation is checked daily by taking it out.

Nach mehreren Tagen resultiert eine Flüssigkeit, die durch das Wachstum der Coli-Bakterien sauer worden ist. In diesem Zustand kommt das Wachstum der Bakterien zum Stillstand. Nach kurzer Erhitzung koaguliert das Eiweiß. Dieses wird abfiltriert und das Filtrat auf Sterilität und Eiweiß freiheit geprüft. Dieses Filtrat kann weiterverarbeitet werden oder auch in der gewonnenen Form zur Anwendung kommen.After several days, the result is a fluid that is created by the growth the coliform bacteria has become acidic. In this state, the bacteria grows to a standstill. After a short period of heating, the protein coagulates. This is filtered off and the filtrate is checked for sterility and freedom from protein. This filtrate can are further processed or can also be used in the form obtained.

Claims (1)

PATENTANSPRUCH: Die Verwendung von menschlichen Ascites oder Blutserum bei der submersen Züchtung von Coli-Bakterien in bekannten Nährlösungen zur Gewinnung von Stoffwechselprodukten mit das Bakterienwachstum - hemmender Wirkung. PATENT CLAIM: The use of human ascites or blood serum in the submerged cultivation of Coli bacteria in known nutrient solutions for extraction of metabolic products with bacterial growth - inhibiting effect. In Betracht gezogene Druckschriften: Klinisches Wörterbuch, I952, S. 78; Klinische Wochensohrift 28, I950, S717 bis 7I9; Chem. Zentralblatt, I95I, II., S. 75 und 837. Publications Considered: Clinical Dictionary, I952, P. 78; Clinical Wochensohrift 28, I950, S717 to 7I9; Chem. Zentralblatt, I95I, II., Pp. 75 and 837.
DEL16639A 1953-09-15 1953-09-15 Manufacture of metabolic products that inhibit bacterial growth Expired DE954910C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEL16639A DE954910C (en) 1953-09-15 1953-09-15 Manufacture of metabolic products that inhibit bacterial growth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEL16639A DE954910C (en) 1953-09-15 1953-09-15 Manufacture of metabolic products that inhibit bacterial growth

Publications (1)

Publication Number Publication Date
DE954910C true DE954910C (en) 1956-12-27

Family

ID=7260493

Family Applications (1)

Application Number Title Priority Date Filing Date
DEL16639A Expired DE954910C (en) 1953-09-15 1953-09-15 Manufacture of metabolic products that inhibit bacterial growth

Country Status (1)

Country Link
DE (1) DE954910C (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Similar Documents

Publication Publication Date Title
DE2010654C3 (en) Normalization of the intestinal flora of humans and pets
CN108703286A (en) A kind of compound fruit enzyme nutrient solution of lemon and its preparation method and application
EP0699442B1 (en) Use of a strain of the fungus fusarium as a producer of substances and a preparation based on said substances with adaptogenic and immunomodulating properties
DE954910C (en) Manufacture of metabolic products that inhibit bacterial growth
DE60117388T2 (en) Composition for the prophylaxis and treatment of cancer
DE2558537C2 (en) Method for isolating substances with insulin-like activity from blood or blood components of calves or pigs
EP0065246A2 (en) Process for producing anabolic, respiration promoting, low-molecular-weight-active substances for prophylactic, therapeutic and cell and tissue culture technique purposes
DE3536342A1 (en) Medicine from milk, milk products and juices from fruit, fruit plants and vegetables containing lactic acid
DE2421084A1 (en) Compsns. contg. Bifidobacterium longum - for animal, esp. pig, rearing and therapy
DEL0016639MA (en)
DE802332C (en) Process for the production of tasteless yeast and yeast extracts or yeast preparations
DE10352822A1 (en) Use of an additionally fermented cereal sludge for the prevention and / or treatment of elevated blood sugar levels
DE424188C (en) Process for the production of a healing serum against cancerous tumors u. like
DE1767914C3 (en) Process for the isolation of microbially produced hydrolytic enzymes
EP3362551B1 (en) Nutrient medium for osmotolerant microorganisms
DE69512279T2 (en) METHOD FOR PRODUCING SPIROLAXIN AND SPIROLAXIN METHYL ETHER
DE698833C (en) Protective bushing for rotating shafts
DE964089C (en) Process for the biological production of vitamin B.
DE937248C (en) Process for the production of nutritional solutions for breeding micromycetes
RU2587046C1 (en) Oil extracts based on enriched plant material
DE884856C (en) Process for the production of preparations containing the anti-pernicious anaemic factor
AT220292B (en) Process for the production of vitamins of the B12 group by propionic acid bacteria
DE392055C (en) Process for the extraction of substances similar to immune bodies
AT148159B (en) Process for the production of dietetic foods.
DE651062C (en) Process for the production of substances which dissolve carcinoma cells or sarcoma cells